FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Virgil Brown

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Risk Factors

Procedures

Clinical Trials as Topic

Co-author Network

Publications

TOP 3
W Virgil Brown
From the editor: Learning from defects.
W Virgil Brown; Terry A Jacobson; Lynne T Braun
Achieving adherence to lipid-lowering regimens.
W Virgil Brown
From the editor: selling the benefit of drug therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Virgil Brown (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: W Virgil Brown
From the editor: Learning from defects.
Journal of clinical lipidology 2013;7(2):91-2.
2013: W Virgil Brown; Terry A Jacobson; Lynne T Braun
Achieving adherence to lipid-lowering regimens.
Journal of clinical lipidology 2013;7(1):4-13.
2013: W Virgil Brown
From the editor: selling the benefit of drug therapy.
Journal of clinical lipidology 2013;7(1):1-2.
2012: W Virgil Brown; Kevin C Maki; Harold E Bays; Robert A Wild
Planning a clinical trial.
Journal of clinical lipidology 2012;6(6):484-95.
2012: W Virgil Brown
From the editor.
Journal of clinical lipidology 2012;6(6):481-2.
2012: W Virgil Brown; John D Brunzell; Robert H Eckel; Neil J Stone
Severe hypertriglyceridemia.
Journal of clinical lipidology 2012;6(5):397-408.
2012: W Virgil Brown
From the editor: the enigma of hypertriglyceridemia.
Journal of clinical lipidology 2012;6(5):393-4.
2012: Tanya N Turan; Nicole Vilardo; Carole L White; Oscar Benavente; W Virgil Brown; Michelle F Caskey; Marc I Chimowitz; Colin P Derdeyn; Brent M Egan; David Fiorella; Kathie L Hermayer; Scott Janis; Bethany Lane; Ngoc-Anh Le; Maria F Lopes-Virella; Michael J Lynn; Azhar Nizam; Meghan R Steiner; Andrew Stufflebean
Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.
Circulation. Cardiovascular quality and outcomes 2012;5(5):e51-60.
2012: W Virgil Brown
From the editor: what are the important questions for clinical trials?
Journal of clinical lipidology 2012;6(4):299-300.
2012: W Virgil Brown; Jan Breslow; Christie Ballantyne
Clinical use of genetic typing in human lipid disorders.
Journal of clinical lipidology 2012;6(3):199-207.
2012: Maju Mathew Koola; Ngoc-Anh Le; Clifford Qualls; Jeffrey Raines; W Virgil Brown; Bruce Cuthbert; Jeffrey P Hollis; Deanna L Kelly; Erica J Duncan
Reduced arterial compliance in patients with psychiatric diagnoses.
Schizophrenia research 2012;137(1-3):251-3.
2012: W Virgil Brown; Linda C Hemphill; Robert Brook; Patrick M Moriarty
The use of lipopheresis in the practice of clinical lipidology.
Journal of clinical lipidology 2012;6(2):98-104.
2012: W Virgil Brown
Medications that lower low-density lipoprotein (LDL) cholesterol and non–high-density lipoprotein (non-HDL) cholesterol.
Journal of clinical lipidology 2012;6(2):95.
2011: W Virgil Brown; William Harris; Harold Bays; Michael Miller
Using omega-3 fatty acids in the practice of clinical lipidology.
Journal of clinical lipidology 2011;5(6):424-33.
2011: W Virgil Brown
From the editor.
Journal of clinical lipidology 2011;5(6):421.
2011: Michael H Davidson; Christie M Ballantyne; Vera A Bittner; Lynne T Braun; Alan S Brown; W Virgil Brown; William C Cromwell; Ronald B Goldberg; Terry A Jacobson; Kevin C Maki; James M McKenney; Alan T Remaley; Allan D Sniderman; Peter P Toth; Sotirios Tsimikas; Paul E Ziajka; Mary R Dicklin
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
Journal of clinical lipidology 2011;5(5):338-67.
2011: W Virgil Brown
Framingham Heart Study.
Journal of clinical lipidology 2011;5(5):335.
2011: W Virgil Brown; George Bakris; Edgar Lerma; Glenn Chertow
Assessment and management of vascular disease risk in patients with chronic kidney disease.
Journal of clinical lipidology 2011;5(4):251-60.
2011: W Virgil Brown
From the editor.
Journal of clinical lipidology 2011;5(4):247-8.
2011: W Virgil Brown
From the editor. Foreword.
Journal of clinical lipidology 2011;5(3):121.
2011: W Virgil Brown; Harold Bays; Michael Davidson; Anne Goldberg
Drugs in development for management of lipoprotein disorders.
Journal of clinical lipidology 2011;5(2):66-75.
2011: W Virgil Brown
Current approaches to arteriosclerosis.
Journal of clinical lipidology 2011;5(2):61-3.
2011: Henry N Ginsberg; W Virgil Brown
Apolipoprotein CIII: 42 years old and even more interesting.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(3):471-3.
2011: W Virgil Brown; Ronald B Goldberg; Maria Lopes-Virella; Peter Reaven
Reducing vascular disease risk in the type 2 diabetic patient.
Journal of clinical lipidology 2011;5(1):3-11.
2010: W Virgil Brown; Don P Wilson; Michael Freemark; Peter O Kwiterovich
The use of lipid-lowering drugs in children.
Journal of clinical lipidology 2010;4(6):449-61.
2010: JoAnne M Foody; W Virgil Brown; Franklin Zieve; Adeniyi J Adewale; Doreen Flaim; Robert S Lowe; Charlotte Jones-Burton; Andrew M Tershakovec
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
The American journal of cardiology 2010;106(9):1255-63.
2010: W Virgil Brown; Nanette Wenger; Vera Bittner; Eliot Brinton
Assessing and addressing risk of cardiovascular disease in perimenopausal and early postmenopausal women.
Journal of clinical lipidology 2010;4(5):324-34.
2010: W Virgil Brown
Publications from two symposia of the National Lipid Association (NLA) Annual Scientific Sessions held May 14 to 16, 2010 in Chicago. Foreword.
Journal of clinical lipidology 2010;4(5):321-2.
2010: W Virgil Brown; Christie M Ballantyne; Peter H Jones; Santica Marcovina
Management of Lp(a).
Journal of clinical lipidology 2010;4(4):240-7.
2010: W Virgil Brown
Inflammatory markers and treatment of elevated LDL-C. Foreword.
Journal of clinical lipidology 2010;4(4):237.
2010: W Virgil Brown; Gary L Myers; Allan D Sniderman; Evan Stein
Should we use apoB for risk assessment and as a target for treatment?
Journal of clinical lipidology 2010;4(3):144-51.
2010: W Virgil Brown
Estimating risk and setting targets for treatment in the national effort to reduce cardiovascular diseases. Foreword.
Journal of clinical lipidology 2010;4(3):139-41.
2010: W Virgil Brown
Risk of vascular disease development and recurrence. Foreword.
Journal of clinical lipidology 2010;4(2):77-8.
2010: W Virgil Brown; H Bryan Brewer; Daniel J Rader; Ernst J Schaefer
HDL as a treatment target.
Journal of clinical lipidology 2010;4(1):5-16.
2010: W Virgil Brown
The disparity between the very strong performance of high-density lipoprotein (HDL) cholesterol as a risk factor and the very weak effects. Foreword.
Journal of clinical lipidology 2010;4(1):1.
2009: W Virgil Brown; Gerald F Fletcher; Peter W Wilson
Using exercise to reduce risk.
Journal of clinical lipidology 2009;3(6):360-7.
2009: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2009;3(6):357.
2009: W Virgil Brown; Wahida Karmally; Penny Kris-Etherton; Lawrence R Rudel
Discussion on dietary fat.
Journal of clinical lipidology 2009;3(5):303-14.
2009: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2009;3(5):299-300.
2009: W Virgil Brown; Alan S Brown; Paolo Raggi; Laurence S Sperling
Appropriate use of noninvasive vascular measures in the prevention of arterial disease.
Journal of clinical lipidology 2009;3(4):250-61.
2009: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2009;3(4):241.
2009: W Virgil Brown; Anne C Goldberg; John R Guyton; Robert H Knopp
The use of niacin.
Journal of clinical lipidology 2009;3(2):65-9.
2009: W Virgil Brown
From the editor.
Journal of clinical lipidology 2009;3(2):61-2.
2009: W Virgil Brown; Ken Fujioka; Peter W F Wilson; Kristina A Woodworth
Obesity: why be concerned?
The American journal of medicine 2009;122(4 Suppl 1):S4-11.
2009: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2009;3(1):1.
2008: W Virgil Brown
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
The American journal of cardiology 2008;102(12A):10L-13L.
2008: W Virgil Brown
From the Editor-in-chief.
Journal of clinical lipidology 2008;2(6):403.
2008: W Virgil Brown
Safety of statins.
Current opinion in lipidology 2008;19(6):558-62.
2008: Jean-Charles Fruchart; Frank Sacks; Michel P Hermans; Gerd Assmann; W Virgil Brown; Richard Ceska; M John Chapman; Paul M Dodson; Paola Fioretto; Henry N Ginsberg; Takashi Kadowaki; Jean-Marc LaBlanche; Nikolaus Marx; Jorge Plutzky; Zeljko Reiner; Robert S Rosenson; Bart Staels; Jane K Stock; Rody Sy; Christoph Wanner; Alberto Zambon; Paul Zimmet
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
The American journal of cardiology 2008;102(10 Suppl):1K-34K.
2008: Jean-Charles Fruchart; Frank M Sacks; Michel P Hermans; Gerd Assmann; W Virgil Brown; Richard Ceska; M John Chapman; Paul M Dodson; Paola Fioretto; Henry N Ginsberg; Takashi Kadowaki; Jean-Marc LaBlanche; Nikolaus Marx; Jorge Plutzky; Zeljko Reiner; Robert S Rosenson; Bart Staels; Jane K Stock; Rody Sy; Christoph Wanner; Alberto Zambon; Paul Zimmet
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2008;5(4):319-35.
2008: W Virgil Brown; Luther Clark; James M Falko; John R Guyton; Tomas J Rees; Gustav Schonfeld; Maria F Lopes-Virella
Optimal management of lipids in diabetes and metabolic syndrome.
Journal of clinical lipidology 2008;2(5):335-42.
2008: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2008;2(5):311.
2008: Mahdi O Garelnabi; W Virgil Brown; Ngoc-Anh Le
Evaluation of a novel colorimetric assay for free oxygen radicals as marker of oxidative stress.
Clinical biochemistry 2008;41(14-15):1250-4.
2008: W Virgil Brown
Comment from the editor.
Journal of clinical lipidology 2008;2(4):308.
2008: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2008;2(4):233.
2008: David G Harrison; W Virgil Brown; Paolo Raggi
Enhanced hype.
The American journal of cardiology 2008;102(3):368-9.
2008: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2008;2(3):113.
2008: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2008;2(2):67-8.
2008: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2008;2(1):1.
2007: Matthey T Harris; Warren W Davis; Ngoc-Anh Le; Barry Eggleston; Garth E Austin; Mohamad Moussa; W Virgil Brown
Free oxygen radicals in whole blood correlate strongly with high-sensitivity C-reactive protein.
Journal of clinical lipidology 2007;1(6):593-8.
2007: Louis J Aronne; W Virgil Brown; Kathy Keenan Isoldi
Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies.
Journal of clinical lipidology 2007;1(6):575-82.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(6):561.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(5):301.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(4):225-6.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(3):171.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(2):97-9.
2007: W Virgil Brown
Expert commentary: the safety of fibrates in lipid-lowering therapy.
The American journal of cardiology 2007;99(6A):19C-21C.
2007: W Virgil Brown
From the Editor-in-Chief.
Journal of clinical lipidology 2007;1(1):1-2.
2006: W Virgil Brown
Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease.
Nature clinical practice. Endocrinology & metabolism 2006;2(9):492-3.
2006: David Rimland; Jodie L Guest; Isabel Hernández-Ramos; Carlos del Rio; Ngoc-Anh Le; W Virgil Brown
Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol.
Journal of acquired immune deficiency syndromes (1999) 2006;42(3):307-13.
2005: David Rimland; Jodie L Guest; I Hernández; Carlos del Rio; Ngoc-Anh Le; W Virgil Brown
Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
HIV medicine 2005;6(5):326-33.
2005: Howard J Willens; Julio A Chirinos; W Virgil Brown; Warren W Davis; David M Herrington; Lori Mosca; Shunichi Homma; Mohamad Moussa; Gail R. Walker; Jeffrey K Raines
Usefulness of arterial compliance in the thigh in predicting exercise capacity in individuals without coronary heart disease.
The American journal of cardiology 2005;96(2):306-10.
2005: Ngoc-Anh Le; W Virgil Brown; Warren W Davis; David M Herrington; Lori Mosca; Shunichi Homma; Barry Eggleston; Howard J Willens; Jeffrey K Raines
Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men.
The American journal of cardiology 2005;95(9):1049-54.
2005: Richard L Klein; M Brent McHenry; Kerry H Lok; Steven J Hunter; Ngoc-Anh Le; Alicia J Jenkins; Deyi Zheng; Andrea J Semler; Grier Page; W Virgil Brown; Timothy J Lyons; W Timothy Garvey
Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort.
Journal of diabetes and its complications 2005;19(1):18-25.
2004: James M McKenney; W Virgil Brown; Jerome D Cohen; Edward Cahill
The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea?
The American journal of cardiology 2004;94(9A):16F-21F.
2004: Richard C Pasternak; James M McKenney; W Virgil Brown; Edward Cahill; Jerome D Cohen
Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys.
The American journal of cardiology 2004;94(9A):9F-15F.
2004: Gocha Saliashvili; Warren W Davis; Matthey T Harris; Ngoc-Anh Le; W Virgil Brown
Simvastatin improved arterial compliance in high-risk patients.
Vascular and endovascular surgery 2004;38(6):519-23.
2004: Richard L Klein; M Brent McHenry; Kerry H Lok; Steven J Hunter; Ngoc-Anh Le; Alicia J Jenkins; Deyi Zheng; Andrea J Semler; W Virgil Brown; Timothy J Lyons; W Timothy Garvey
Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
Metabolism: clinical and experimental 2004;53(10):1296-304.
2004: Nader Rifai; Gerald R Cooper; W Virgil Brown; William Friedewald; Richard J Havel; Gary L Myers; G Russell Warnick
Clinical Chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years.
Clinical chemistry 2004;50(10):1861-70.
2004: James M McKenney; J Chris Bradberry; Robert L Talbert; Edward Cahill; W Virgil Brown
National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists' services.
Journal of the American Pharmacists Association : JAPhA 2004;44(5):562-8.
2004: David M Herrington; W Virgil Brown; Lori Mosca; Warren Davis; Barry Eggleston; W Gregory Hundley; Jeffrey K Raines
Relationship between arterial stiffness and subclinical aortic atherosclerosis.
Circulation 2004;110(4):432-7.
2004: W Quinten Gradek; Matthey T Harris; Najat Yahia; Warren W Davis; Ngoc-Anh Le; W Virgil Brown
Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified lipoproteins in patients with vascular disease.
The American journal of cardiology 2004;93(7):881-5.
2004: W Virgil Brown
Metabolic syndrome and risk of stroke.
Clinical cornerstone 2004;6 Suppl 3():S30-4.
2003: W Virgil Brown; Mohamad Moussa
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Current opinion in lipidology 2003;14(6):593-7.
2003: Emelita D Breyer; Sarah Howard; Neeta Raje; Stuart Allison; Robert P Apkarian; W Virgil Brown; Joost K Strasters
Study of lipid and apolipoprotein binding interactions using vesicle affinity capillary electrophoresis.
Analytical chemistry 2003;75(19):5160-9.
2003: David M Herrington; Karen Kesler; J h C Reiber; Warren Davis; W Virgil Brown; Ronald Helms; Stephen Mallon; Jeffrey K Raines
Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease.
American heart journal 2003;146(4):662-7.
2003: W Virgil Brown; Warren Davis; Matthey Harris
Implications of the heart protection study for reducing coronary events in high-risk patients.
Current atherosclerosis reports 2003;5(5):358-63.
2003: W Virgil Brown
Cholesterol absorption inhibitors: defining new options in lipid management.
Clinical cardiology 2003;26(6):259-64.
2003: Howard J Willens; Warren Davis; David M Herrington; Karen Wade; Karen Kesler; Stephen Mallon; W Virgil Brown; J H C Reiber; Jeffrey K Raines
Relationship of peripheral arterial compliance and standard cardiovascular risk factors.
Vascular and endovascular surgery 2003;37(3):197-206.
2003: Matthey Harris; Warren Davis; W Virgil Brown
Ezetimibe.
Drugs of today (Barcelona, Spain : 1998) 2003;39(4):229-47.
2003: W Virgil Brown
Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes.
Clinical cardiology 2003;26(4 Suppl 3):III13-8.
2003: W Virgil Brown
Reaching goal: conquering the treatment gaps in dyslipidemia management.
Clinical cardiology 2003;26(4 Suppl 3):III1-2.
2003: James W Blasetto; Evan A Stein; W Virgil Brown; Rohini R Chitra; Ali Raza
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
The American journal of cardiology 2003;91(5A):3C-10C; discussion 10C.
2003: Dennis L Sprecher; Timothy R Watkins; Solomon Behar; W Virgil Brown; Hanna Bloomfield Rubins; Ernst Schaefer
Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease.
The American journal of cardiology 2003;91(5):575-80.
2002: W Virgil Brown; Harold E Bays; David R Hassman; James McKenney; Rohini R Chitra; Howard Hutchinson; Elinor Miller
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
American heart journal 2002;144(6):1036-43.
2002: W Virgil Brown
Promising therapies for cholesterol reduction.
Managed care (Langhorne, Pa.) 2002;11(9 Suppl):10-4.
2001: W Virgil Brown
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
The Journal of the American Osteopathic Association 2001;101(9 Suppl):S6-11.
2001: W Virgil Brown
What are the priorities for managing cholesterol effectively?
The American journal of cardiology 2001;88(4A):21F-4F.
2001: W Virgil Brown
Therapies on the horizon for cholesterol reduction.
Clinical cardiology 2001;24(8 Suppl):III24-7.
2001: W Virgil Brown
Statin therapy in the new millennium: is there room for improvement?
Clinical cardiology 2001;24(8 Suppl):III1-2.
2001: W Virgil Brown
New therapies on the horizon.
The American journal of managed care 2001;7(5 Suppl):S148-51.
2001: W Virgil Brown
Novel approaches to lipid lowering: what is on the horizon?
The American journal of cardiology 2001;87(5A):23B-27B.
2000: W Virgil Brown
Risk factors for vascular disease in patients with diabetes.
Diabetes, obesity & metabolism 2000;2 Suppl 2():S11-8.
2000: Ngoc-Anh Le; X Li; S Kyung; W Virgil Brown
Evidence for the in vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium.
Metabolism: clinical and experimental 2000;49(10):1271-7.
2000: W Virgil Brown
The benefit of aggressive lipid lowering.
Atherosclerosis. Supplements 2000;1(1):15-9.
2000: W Virgil Brown
Cholesterol lowering in atherosclerosis.
The American journal of cardiology 2000;86(4B):29H-32H.
2000: James W Anderson; M H Davidson; L Blonde; W Virgil Brown; W J Howard; Henry N Ginsberg; LD Allgood; K W Weingand
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia.
The American journal of clinical nutrition 2000;71(6):1433-8.
2000: Ngoc-Anh Le; W Innis-Whitehouse; X Li; R Bakker-Arkema; D Black; W Virgil Brown
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Metabolism: clinical and experimental 2000;49(2):167-77.
1999: Emelita D Breyer; Ngoc-Anh Le; X Li; Deborah E Martinson; W Virgil Brown
Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
Journal of lipid research 1999;40(10):1875-82.
1999: Bertram Pitt; D Waters; W Virgil Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
The New England journal of medicine 1999;341(2):70-6.
1998: JS Schwartz; W Virgil Brown; M Hlatky; WP Castelli
Cardiovascular disease and lipoproteins: available evidence and remaining questions. Reactor panel and open forum.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 1998;1(2):125-30.
1998: W Virgil Brown
Landmark trials in lipid reduction.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 1998;1(2):110-4.
1998: W Innis-Whitehouse; X Li; W Virgil Brown; Ngoc-Anh Le
An efficient chromatographic system for lipoprotein fractionation using whole plasma.
Journal of lipid research 1998;39(3):679-90.
1998: W Virgil Brown
Impact of dyslipidaemia. Lessons from clinical trials.
PharmacoEconomics 1998;14 Suppl 3():1-9.
1997: X Li; W Innis-Whitehouse; W Virgil Brown; Ngoc-Anh Le
Protocol for the preparation of a segmental linear polyacrylamide gradient gel: simultaneous determination of Lp[a], LDL, and HDL particle sizes.
Journal of lipid research 1997;38(12):2603-14.
1997: L S McCormick; DM Black; D Waters; W Virgil Brown; Bertram Pitt
Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).
The American journal of cardiology 1997;80(9):1130-3.
1997: A Hulton; R Rothenberg; W Virgil Brown; H Maibach
Basic demographic and professional characteristics of US women physicians.
The Western journal of medicine 1997;166(3):179-84.
1997: W Virgil Brown
Hypercholesterolemia in the United States: how far have we come?
The American journal of medicine 1997;102(2A):3-6.
1997: W Virgil Brown
Epidemiology and treatment of hypercholesterolemia: where we are today. Introduction.
The American journal of medicine 1997;102(2A):1-2.
1996: William S Weintraub; N K Wenger; Sampath Parthasarathy; W Virgil Brown
Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate.
Journal of clinical epidemiology 1996;49(12):1353-8.
1996: RG Bakker-Arkema; Michael H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; Stuart R Weiss; L M Keilson; W Virgil Brown; V T Miller; L J Shurzinske; DM Black
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
JAMA : the journal of the American Medical Association 1996;275(2):128-33.
1995: W Virgil Brown
Niacin for lipid disorders. Indications, effectiveness, and safety.
Postgraduate medicine 1995;98(2):185-9, 192-3.
1994: W Virgil Brown
Hydroxymethylglutaryl coenzyme a reductase inhibition: fluvastatin, a clinical investigators' update. Introduction.
The American journal of cardiology 1994;73(14):1D-2D.
1994: W Virgil Brown
Lipoprotein disorders in diabetes mellitus.
The Medical clinics of North America 1994;78(1):143-61.
1993: J Stamler; R Stamler; W Virgil Brown; A M Gotto; Philip Greenland; S Grundy; D M Hegsted; Russell V Luepker; J D Neaton; D Steinberg
Serum cholesterol. Doing the right thing.
Circulation 1993;88(4 Pt 1):1954-60.
1993: Thomas A Pearson; W Virgil Brown; K Donato; F A Franklin; R B Luepker; P E McBride; R M Mullis; L W Scott; B Shannon; R B Shekelle
Lipids. Workshop IV. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health.
Circulation 1993;88(3):1397-401.
1992: W Virgil Brown
When do we treat hypercholesterolemia?
Clinical cardiology 1992;15(11 Suppl 3):III10-4; discussion III 15-7.
1992: W Virgil Brown
When do we treat hypercholesterolemia?
Clinical cardiology 1992;15(11):III10-4; discussion III15-7.
1992: W Virgil Brown; J L Breslow
Genetic lipoprotein abnormalities producing high blood cholesterol.
Heart disease and stroke : a journal for primary care physicians 1992;1(6):405-7.
1992: K Ishimura-Oka; Clay F Semenkovich; F Faustinella; Ira J Goldberg; Neil S Shachter; Louis C Smith; Trey Coleman; Winston Hide; W Virgil Brown; Kazuhiro Oka
A missense (Asp250----Asn) mutation in the lipoprotein lipase gene in two unrelated families with familial lipoprotein lipase deficiency.
Journal of lipid research 1992;33(5):745-54.
1992: W Virgil Brown
President's address to the 64th scientific sessions of the American Heart Association.
Circulation 1992;85(5):1969-71.
1992: W Virgil Brown
Lipoproteins: what, when, and how often to measure.
Heart disease and stroke : a journal for primary care physicians 1992;1(1):20-6.
1991: L Mishra; N A Le; W Virgil Brown; Esteban Mezey
Effect of acute intravenous alcohol on plasma lipoproteins in man.
Metabolism: clinical and experimental 1991;40(11):1128-30.
1991: Kazuhiro Oka; T Nakano; G T Tkalcevic; R O Scow; W Virgil Brown
Molecular cloning of mouse hepatic triacylglycerol lipase: gene expression in combined lipase-deficient (cld/cld) mice.
Biochimica et biophysica acta 1991;1089(1):13-20.
1990: W Virgil Brown
Review of clinical trials: proving the lipid hypothesis.
European heart journal 1990;11 Suppl H():15-20.
1990: Donald B Hunninghake; Robert H Knopp; Gustav Schonfeld; A C Goldberg; W Virgil Brown; Ernst Schaefer; Simeon Margolis; Adrian S Dobs; M J Mellies; W Insull
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Atherosclerosis 1990;85(1):81-9.
1990: W Virgil Brown
Clinical trials including an update on the Helsinki Heart Study.
The American journal of cardiology 1990;66(6):11A-15A.
1990: Kazuhiro Oka; G T Tkalcevic; T Nakano; H Tucker; K Ishimura-Oka; W Virgil Brown
Structure and polymorphic map of human lipoprotein lipase gene.
Biochimica et biophysica acta 1990;1049(1):21-6.
1990: T Nakano; H Tucker; K Oka; W Virgil Brown
A simple semi-dry capillary transfer of DNA.
BioTechniques 1990;8(2):173-4.
1990: W Virgil Brown; W J Howard
Treatment of lipoprotein disorders.
Cardiovascular clinics 1990;20(3):157-76.
1990: W Virgil Brown
Dietary recommendations to prevent coronary heart disease.
Annals of the New York Academy of Sciences 1990;598():376-88.
1989: S M Grundy; W Virgil Brown; J M Dietschy; Henry N Ginsberg; S Goodnight; B Howard; J C La Rosa; H C McGill
AHA Conference Report on Cholesterol. Basis for dietary treatment.
Circulation 1989;80(3):729-34.
1989: Kazuhiro Oka; G T Tkalcevic; J Stocks; D J Galton; W Virgil Brown
Nucleotide sequence of PvuII polymorphic site at the human lipoprotein lipase gene locus.
Nucleic acids research 1989;17(16):6752.
1989: K Oka; J G Yuan; M Senda; A S Masibay; P K Qasba; Hiroshi Masuno; R O Scow; J R Paterniti; W Virgil Brown; P K Oasba
Expression of lipoprotein lipase gene in combined lipase deficiency.
Biochimica et biophysica acta 1989;1008(3):351-4.
1989: K Oka; P Wang-Iverson; J R Paterniti; W Virgil Brown
Interaction of lipoprotein lipase with heparin.
Annals of the New York Academy of Sciences 1989;556():173-80.
1989: W Virgil Brown
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Cardiology 1989;76 Suppl 1():45-51; discussion 52-4.
1989: W Virgil Brown
Treatment of hypercholesterolaemia with fenofibrate: a review.
Current medical research and opinion 1989;11(5):321-30.
1988: J C Gibson; W Virgil Brown
Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among the plasma lipoproteins.
Atherosclerosis 1988;73(1):45-55.
1988: W Virgil Brown
The cholesterol hypothesis and the value of intervention.
The Journal of the American Osteopathic Association 1988;88(7):859-64.
1988: W Virgil Brown
Focus on fenofibrate.
Hospital practice (Office ed.) 1988;23 Suppl 1():31-40.
1987: W Virgil Brown
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
The American journal of medicine 1987;83(5B):85-9.
1987: W Virgil Brown
Fenofibrate, a third-generation fibric acid derivative.
The American journal of medicine 1987;83(5B):1-2.
1987: Robert H Knopp; W Virgil Brown; Carlos A Dujovne; J W Farquhar; E B Feldman; A C Goldberg; S M Grundy; N L Lasser; M J Mellies; R H Palmer
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
The American journal of medicine 1987;83(5B):50-9.
1987: D A Smith; W Karmally; W Virgil Brown
Treating hyperlipidemia, Part III: Drug therapy.
Geriatrics 1987;42(8):55-9, 62.
1987: J C Gibson; Ronald B Goldberg; A Rubinstein; Henry N Ginsberg; W Virgil Brown; S Baker; B I Joffe; H C Seftel
Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia.
Arteriosclerosis (Dallas, Tex.) 1987;7(4):401-7.
1987: D A Smith; W Karmally; W Virgil Brown
Treating hyperlipidemia, Part II: Making dietary control work in the elderly.
Geriatrics 1987;42(7):39-40, 42-3.
1987: M Senda; K Oka; W Virgil Brown; P K Qasba; Y Furuichi
Molecular cloning and sequence of a cDNA coding for bovine lipoprotein lipase.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(13):4369-73.
1987: D A Smith; W Karmally; W Virgil Brown
Treating hyperlipidemia, Part I: Whether and when in the elderly.
Geriatrics 1987;42(6):33-6, 39-42, 44.
1987: Z T Bloomgarden; W Karmally; M J Metzger; M Brothers; C Nechemias; J Bookman; D Faierman; F Ginsberg-Fellner; E Rayfield; W Virgil Brown
Randomized, controlled trial of diabetic patient education: improved knowledge without improved metabolic status.
Diabetes care 1987;10(3):263-72.
1986: A Rubinstein; J C Gibson; Henry N Ginsberg; W Virgil Brown
In vitro metabolism of apolipoprotein E.
Biochimica et biophysica acta 1986;879(3):355-61.
1986: I J Goldberg; N A Le; B Leeman; W Virgil Brown; F T Lindgren
Evidence for heterogeneity of low-density lipoprotein metabolism in the cynomolgus monkey.
Biochimica et biophysica acta 1986;879(2):179-85.
1986: W Virgil Brown; Carlos A Dujovne; J W Farquhar; E B Feldman; S M Grundy; Robert H Knopp; N L Lasser; M J Mellies; R H Palmer; P Samuel
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
Arteriosclerosis (Dallas, Tex.) 1986;6(6):670-8.
1986: Henry N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W Virgil Brown
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
The Journal of clinical investigation 1986;78(5):1287-95.
1986: E Joan Blanchette-Mackie; M G Wetzel; S S Chernick; J R Paterniti; W Virgil Brown; R O Scow
Effect of the combined lipase deficiency mutation (cld/cld) on ultrastructure of tissues in mice. Diaphragm, heart, brown adipose tissue, lung, and liver.
Laboratory investigation; a journal of technical methods and pathology 1986;55(3):347-62.
1986: D Faierman; Z T Bloomgarden; C Nechemias; W Virgil Brown
Electrocardiographic abnormalities in diabetes mellitus: association between T-wave changes and nephropathy.
The Mount Sinai journal of medicine, New York 1986;53(4):254-9.
1986: J C Gibson; A Rubinstein; Henry N Ginsberg; W Virgil Brown
Isolation of apolipoprotein E-containing lipoproteins by immunoaffinity chromatography.
Methods in enzymology 1986;129():186-98.
1986: N A Le; P R Bukberg; Henry N Ginsberg; J C Gibson; W Virgil Brown
Direct determination of apolipoprotein C-III specific activity using immunoaffinity chromatography.
Methods in enzymology 1986;129():457-69.
1986: N A Le; R Ramakrishnan; R B Dell; Henry N Ginsberg; W Virgil Brown
Kinetic analysis using specific radioactivity data.
Methods in enzymology 1986;129():384-95.
1986: Henry N Ginsberg; A Rubenstein; W Virgil Brown
Medical complications of isotretinoin.
Clinics in dermatology 1986;4(1):183-9.
1985: S M Grundy; R Arky; G A Bray; W Virgil Brown; N D Ernst; Peter O Kwiterovich; F Mattson; W H Weidman; G Schonfeld; J P Strong
Coronary risk factor statement for the American public. A statement of the nutrition committee.
Circulation 1985;72(5):1135A-1139A.
1985: S Bershad; A Rubinstein; J R Paterniti; N A Le; S C Poliak; B Heller; Henry N Ginsberg; R Fleischmajer; W Virgil Brown
Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne.
The New England journal of medicine 1985;313(16):981-5.
1985: P R Bukberg; N A Le; Henry N Ginsberg; J C Gibson; A Rubinstein; W Virgil Brown
Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.
Journal of lipid research 1985;26(9):1047-57.
1985: Ira J Goldberg; R G Mazlen; A Rubenstein; J C Gibson; J R Paterniti; F T Lindgren; W Virgil Brown
Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency.
Metabolism: clinical and experimental 1985;34(9):832-5.
1985: J C Gibson; A Rubinstein; W Virgil Brown; Henry N Ginsberg; Heiner Greten; R Norum; H Kayden
Apo E-containing lipoproteins in low or high density lipoprotein deficiency.
Arteriosclerosis (Dallas, Tex.) 1985;5(4):371-80.
1985: J C Gibson; A Rubinstein; N Ngai; Henry N Ginsberg; N A Le; R E Gordon; I J Goldberg; W Virgil Brown
Immunoaffinity isolation of apolipoprotein E-containing lipoproteins.
Biochimica et biophysica acta 1985;835(1):113-23.
1985: W Virgil Brown; W Karmally
Coronary heart disease and the consumption of diets high in wheat and other grains.
The American journal of clinical nutrition 1985;41(5 Suppl):1163-71.
1985: P Wang-Iverson; J C Gibson; W Virgil Brown
Plasma apolipoprotein secretion by human monocyte-derived macrophages.
Biochimica et biophysica acta 1985;834(2):256-62.
1985: Thomas Olivecrona; S S Chernick; G Bengtsson-Olivecrona; J R Paterniti; W Virgil Brown; R O Scow
Combined lipase deficiency (cld/cld) in mice. Demonstration that an inactive form of lipoprotein lipase is synthesized.
The Journal of biological chemistry 1985;260(4):2552-7.
1985: A Rubinstein; J C Gibson; J R Paterniti; G Kakis; A Little; Henry N Ginsberg; W Virgil Brown
Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
The Journal of clinical investigation 1985;75(2):710-21.
1985: P Wang-Iverson; Henry N Ginsberg; L A Peteanu; N A Le; W Virgil Brown
Apo E-mediated uptake and degradation of normal very low density lipoproteins by human monocyte/macrophages: a saturable pathway distinct from the LDL receptor.
Biochemical and biophysical research communications 1985;126(1):578-86.
1984: N A Le; Henry N Ginsberg; W Virgil Brown
Protocol for efficient plasma sampling for low density lipoprotein turnover studies.
Journal of lipid research 1984;25(12):1387-91.
1984: Z T Bloomgarden; F Ginsberg-Fellner; E J Rayfield; J Bookman; W Virgil Brown
Elevated hemoglobin A1c and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients.
The American journal of medicine 1984;77(5):823-7.
1984: J C Gibson; A Rubinstein; W Virgil Brown
Precipitation of apo E-containing lipoproteins by precipitation reagents for apolipoprotein B.
Clinical chemistry 1984;30(11):1784-8.
1984: W Virgil Brown; Henry N Ginsberg; W Karmally
Diet and the decrease of coronary heart disease.
The American journal of cardiology 1984;54(5):27C-29C.
1984: W Virgil Brown; I J Goldberg; Henry N Ginsberg
Treatment of common lipoprotein disorders.
Progress in cardiovascular diseases 1984;27(1):1-20.
1983: P R Bukberg; N A Le; Henry N Ginsberg; J C Gibson; L C Goldman; W Virgil Brown
Direct measurement of apoprotein C-III specific activity in 125I-labeled very low density lipoproteins using immunoaffinity chromatography.
Journal of lipid research 1983;24(9):1251-60.
1983: I J Goldberg; J R Paterniti; B H Franklin; Henry N Ginsberg; F Ginsberg-Fellner; W Virgil Brown
Transient lipoprotein lipase deficiency with hyperchylomicronemia.
The American journal of the medical sciences 1983;286(2):28-31.
1983: J R Paterniti; W Virgil Brown; Henry N Ginsberg; K Artzt
Combined lipase deficiency (cld): a lethal mutation on chromosome 17 of the mouse.
Science (New York, N.Y.) 1983;221(4606):167-9.
1983: J C Gibson; A Rubinstein; P R Bukberg; W Virgil Brown
Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects.
Journal of lipid research 1983;24(7):886-98.
1983: I J Goldberg; J R Paterniti; W Virgil Brown
Measurement of lipoprotein lipase and hepatic triacylglycerol lipase in post-heparin plasma of the cynomolgus monkey.
Biochimica et biophysica acta 1983;752(1):172-7.
1983: Henry N Ginsberg; I J Goldberg; P Wang-Iverson; E Gitler; N A Le; H S Gilbert; W Virgil Brown
Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases.
Arteriosclerosis (Dallas, Tex.) 1983;3(3):233-41.
1983: Ira J Goldberg; N A Le; Henry N Ginsberg; J R Paterniti; W Virgil Brown
Metabolism of apoprotein B in cynomolgus monkey: evidence for independent production of low-density lipoprotein apoprotein B.
The American journal of physiology 1983;244(2):E196-201.
1982: Ira J Goldberg; N A Le; J R Paterniti; Henry N Ginsberg; F T Lindgren; W Virgil Brown
Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.
The Journal of clinical investigation 1982;70(6):1184-92.
1982: Henry N Ginsberg; N Davidson; N A Le; J Gibson; E H Ahrens; W Virgil Brown
Marked overproduction of low density lipoprotein apolipoprotein B in a subject with heterozygous familial hypercholesterolemia. Effect of portacaval shunting.
Biochimica et biophysica acta 1982;712(2):250-7.
1982: W Virgil Brown; Z Bloomgarden; Henry N Ginsberg
Lipoproteins as risk factors for vascular disease in diabetes.
The Mount Sinai journal of medicine, New York 1982;49(3):176-86.
1982: S M Grundy; D Bilheimer; H Blackburn; W Virgil Brown; Peter O Kwiterovich; F Mattson; G Schonfeld; W H Weidman
Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee.
Circulation 1982;65(4):839A-854A.
1982: Henry N Ginsberg; H S Gilbert; J C Gibson; N A Le; W Virgil Brown
Increased low-density-lipoprotein catabolism in myeloproliferative disorders.
Annals of internal medicine 1982;96(3):311-6.
1982: P Wang-Iverson; A Ungar; J Bliumis; P R Bukberg; J C Gibson; W Virgil Brown
Human monocytes in culture synthesize and secrete lipoprotein lipase.
Biochemical and biophysical research communications 1982;104(3):923-8.
1982: P Wang-Iverson; W Virgil Brown
Interaction of lipoprotein lipase with cultured endothelial cells.
Annals of the New York Academy of Sciences 1982;401():92-101.
1981: Henry N Ginsberg; N A Le; C Mays; J Gibson; W Virgil Brown
Lipoprotein metabolism in nonresponders to increased dietary cholesterol.
Arteriosclerosis (Dallas, Tex.) 1981;1(6):463-70.
1981: H S Gilbert; Henry N Ginsberg; R Fagerstrom; W Virgil Brown
Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity.
The American journal of medicine 1981;71(4):595-602.
1981: J D Turner; N A Le; W Virgil Brown
Effect of changing dietary fat saturation on low-density lipoprotein metabolism in man.
The American journal of physiology 1981;241(1):E57-63.
1981: Henry N Ginsberg; N A Le; J Melish; D Steinberg; W Virgil Brown
Effect of a high carbohydrate diet on apoprotein-B catabolism in man.
Metabolism: clinical and experimental 1981;30(4):347-53.
1980: J Melish; N A Le; Henry N Ginsberg; D Steinberg; W Virgil Brown
Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins.
The American journal of physiology 1980;239(5):E354-62.
1980: W Virgil Brown
Structure and metabolism of plasma lipoproteins---an overview.
Nutrition and metabolism 1980;24 Suppl 1():1-2.
1979: D Steinberg; S M Grundy; H Y Mok; J D Turner; D B Weinstein; W Virgil Brown; J J Albers
Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypolphalipoproteinemia and fasting chylomicronemia.
The Journal of clinical investigation 1979;64(1):292-301.
1979: E Barrett-Connor; W Virgil Brown; J Turner; M Austin; M H Criqui
Heart disease risk factors and hormone use in postmenopausal women.
JAMA : the journal of the American Medical Association 1979;241(20):2167-9.
1979: M L Baginsky; W Virgil Brown
A new method for the measurement of lipoprotein lipase in postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase.
Journal of lipid research 1979;20(4):548-56.
1979: J Boberg; M Boberg; R Gross; J D Turner; J Augustin; W Virgil Brown
Hepatic triglyceride and lipoprotein lipase activities of post-heparin plasma in normals and hypertriglyceridemics.
Upsala journal of medical sciences 1979;84(3):215-27.
1978: N A Le; J S Melish; B C Roach; Henry N Ginsberg; W Virgil Brown
Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins.
Journal of lipid research 1978;19(5):578-84.
1978: J Augustin; H Freeze; P Tejada; W Virgil Brown
A comparison of molecular properties of hepatic triglyceride lipase and lipoprotein lipase from human post-heparin plasma.
The Journal of biological chemistry 1978;253(9):2912-20.
1977: J Boberg; J Augustin; M L Baginsky; P Tejada; W Virgil Brown
Quantitative determination of hepatic and lipoprotein lipase activities from human postheparin plasma.
Journal of lipid research 1977;18(4):544-7.
1977: M L Baginsky; W Virgil Brown
Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma.
Journal of lipid research 1977;18(4):423-37.
1977: C Ehnholm; A Bensadoun; W Virgil Brown
Characterization of two triacylglycerol lipase activities in pig post-heparin plasma.
The Biochemical journal 1977;163(2):347-55.
1977: Peter O Kwiterovich; J R Farah; W Virgil Brown; P S Bachorik; Stephen B Baylin; C A Neill
The clinical, biochemical, and familial presentation of type V hyperlipoproteinemia in childhood.
Pediatrics 1977;59(4):513-25.
1977: W Virgil Brown; E B Collins
End products and fermentation balances for lactic streptococci grown aerobically on low concentrations of glucose.
Applied and environmental microbiology 1977;33(1):38-42.
1976: M Rosseneu; F Soetewey; G Middelhoff; H Peeters; W Virgil Brown
Studies of the lipid binding characteristics of the apolipoproteins from human high density lipoprotein. II. Calorimetry of the binding of apo AI and apo AII with phospholipids.
Biochimica et biophysica acta 1976;441(1):68-80.
1976: G Middelhoff; M Rosseneu; H Peeters; W Virgil Brown
Study of the lipid binding characteristics of the apolipoproteins from human high density lipoprotein. I. Electron microscopic and gel filtration studies with synthetic phosphatidylcholines.
Biochimica et biophysica acta 1976;441(1):57-67.
1976: M L Baginsky; W Virgil Brown
Effects of monoolein on hydrolysis of triglyceride by lipoprotein lipase in the presence of an inhibitory apolipoprotein.
Physiological chemistry and physics 1976;8(3):197-206.
1975: C Ehnholm; W Shaw; Heiner Greten; W Virgil Brown
Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids.
The Journal of biological chemistry 1975;250(17):6756-61.
1974: S Wetmore; R W Mahley; W Virgil Brown; H Schachter
Incorporation of sialic acid into sialidase-treated apolipoprotein of human, very low density lipoprotein by a pork liver sialytransferase.
Canadian journal of biochemistry 1974;52(8):654-64.
1974: C Cottrill; C J Glueck; V Leuba; F Millett; D Puppione; W Virgil Brown
Familial homozygous hypobetalipoproteinemia.
Metabolism: clinical and experimental 1974;23(8):779-91.
1974: C Ehnholm; Heiner Greten; W Virgil Brown
A comparative study of post-heparin lipolytic activity and a purified human plasma triacylglycerol lipase.
Biochimica et biophysica acta 1974;360(1):68-77.
1974: A D Sniderman; J G Chandler; D Steinberg; W Virgil Brown
Evidence for the hepatic origin of a canine post-heparin plasma triglyceride lipase.
FEBS letters 1974;42(2):157-60.
1974: A Bensadoun; C Ehnholm; D Steinberg; W Virgil Brown
Purification and characterization of lipoprotein lipase from pig adipose tissue.
The Journal of biological chemistry 1974;249(7):2220-7.
1974: W Virgil Brown; M L Baginsky
Some functional aspects of apolipoproteins: apoLp-Ala inhibition of lipoprotein lipase and deinhibition by monoolein.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1974;Suppl 4():11-6.
1973: R I Levy; D S Fredrickson; N J Stone; D W Bilheimer; W Virgil Brown; C J Glueck; A M Gotto; P N Herbert; Peter O Kwiterovich; T Langer; J LaRosa; S E Lux; A K Rider; R S Shulman; H R Sloan
Cholestyramine in type II hyperlipoproteinemia. A double-blind trial.
Annals of internal medicine 1973;79(1):51-8.
1973: W Virgil Brown; Heiner Greten
Type I hyperlipoproteinaemia.
Clinics in endocrinology and metabolism 1973;2(1):73-80.
1972: A M Gotto; W Virgil Brown; R I Levy; M E Birnbaumer; D S Fredrickson
Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia.
The Journal of clinical investigation 1972;51(6):1486-94.
1972: W Virgil Brown; M L Baginsky
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.
Biochemical and biophysical research communications 1972;46(2):375-82.
1972: W Virgil Brown
Some functional aspects of the plasma apolipoproteins.
Verhandlungen der Deutschen Gesellschaft für Innere Medizin 1972;78():1292.
1971: J C LaRosa; R I Levy; W Virgil Brown; D S Fredrickson
Changes in high-density lipoprotein protein composition after heparin-induced lipolysis.
The American journal of physiology 1971;220(3):785-91.
1970: W Virgil Brown; R I Levy; D S Fredrickson
Further characterization of apolipoproteins from the human plasma very low density lipoproteins.
The Journal of biological chemistry 1970;245(24):6588-94.
1970: T P Bersot; W Virgil Brown; R I Levy; H G Windmueller; D S Fredrickson; V S LeQuire
Further characterization of the apolipoproteins of rat plasma lipoproteins.
Biochemistry 1970;9(17):3427-33.
1970: R W Mahley; T P Bersot; V S LeQuire; R I Levy; H G Windmueller; W Virgil Brown
Identity of very low density lipoprotein apoproteins of plasma and liver Golgi apparatus.
Science (New York, N.Y.) 1970;168(3929):380-2.
1970: W Virgil Brown; R I Levy; D S Fredrickson
Further separation of the apoproteins of the human plasma very low density lipoproteins.
Biochimica et biophysica acta 1970;200(3):573-5.
1969: W Virgil Brown; R I Levy; D S Fredrickson
Studies of the proteins in human plasma very low density lipoproteins.
The Journal of biological chemistry 1969;244(20):5687-94.
1969: C J Glueck; W Virgil Brown; Heiner Greten; R I Levy; D S Fredrickson
Treatment of hypertriglyceridaemia.
Lancet 1969;2(7625):852.
1969: C J Glueck; W Virgil Brown; R I Levy; Heiner Greten; D S Fredrickson
Amelioration of hypertriglyceridaemia by progestational drugs in familial type-V hyperlipoproteinaemia.
Lancet 1969;1(7609):1290-1.
1969: J C La Rosa; W Virgil Brown; P L Frommer; R I Levy
Clofibrate-induced ventricular arrhythmia.
The American journal of cardiology 1969;23(2):266-9.